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Background: Physical therapy for the treatment of lateral epicondylitis (LE) often comprises movement therapies,
extracorporeal shockwave therapy (ECSWT), low level laser therapy (LLLT), low frequency electrical stimulation or
pulsed electromagnetic fields. Still, only ECSWT and LLLT have been meta-analytically researched.
Methods: PUBMED, EMBASE and Cochrane database were systematically searched for randomized controlled trials
(RCTs). Methodological quality of each study was rated with an adapted version of the Scottish Intercollegiate
Guidelines Network (SIGN) checklist. Pain reduction (the difference between treatment and control groups at the
end of trials) and pain relief (the change in pain from baseline to the end of trials) were calculated with mean
differences (MD) and 95 %-Confidence intervals (95 % CI).
Results: One thousand one hundred thirty eight studies were identified. One thousand seventy of those did not
meet inclusion criteria. After full articles were retrieved 16 studies met inclusion criteria and 12 studies reported
comparable outcome variables. Analyses were conducted for overall pain relief, pain relief during maximum
handgrip strength tests, and maximum handgrip strength. There were not enough studies to conduct an analysis
of physical function or other outcome variables.
Conclusions: Differences between treatment and control groups were larger than differences between treatments.
Control group gains were 50 to 66 % as high as treatment group gains. Still, only treatment groups with their
combination of therapy specific and non-therapy specific factors reliably met criteria for clinical relevance. Results
are discussed with respect to stability and their potential meaning for the use of non-therapy specific agents to
optimize patients’ gain.Background
Lateral epicondylitis (LE) is a painful musculoskeletal
condition caused by overuse. The injury of the common
extensor tendon originating from the lateral epicondyle
is better known as tennis elbow. Both names are mis-
leading though, since it is neither an inflammatory con-
dition, nor does it only occur in tennis players. Other
sports and jobs involving highly repetitive movements
are strong contributors to the overuse-injury. It mostly
affects people 40 years and older. Some studies indicate
that men and women are equally affected [1], others re-
port a higher percentage of affected women [1, 2]. The* Correspondence: weber@diempuberater.de
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[2]. The National Guidelines Clearinghouse [3] recom-
mends to first inform patients about the condition and
to instruct them further to avoid aggravation [3]. The
first pharmacological approach is to prescribe nonsteroi-
dal anti-inflammatory drugs (NSAIDs). Also injection
therapies for lateral epicondylitis are suggested. In a sys-
tematic review [4] the effects of prolotherapy, polidoca-
nol, whole blood and platelet-rich plasma on lateral
epicondylitis were measured. Strong pilot-level evidence
was found but all studies were limited by small sample
size. Newer studies showed small to none effects of in-
jection therapies on pain and disability [5, 6]. In general,
treatments like splinting, stretching and strengthening
exercises, soft tissue mobilisation and acupuncture are
recommended [3].
Research on physical treatments for LE has not yet
proven superiority of one specific approach. A meta-is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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to no superiority of shock wave therapy over placebo
and Bjordal et al. [7] found only short term effects of
low level laser therapy (LLLT) over placebo. Both meta-
analyses focused on one form of physical treatment.
The aim of this study was to meta-analyse the empirical
evidence for physical treatments for LE and give practi-
tioners an estimate of what benefits patients might expect
from various treatments, both based on treatment specific
and non-specific agents. Outcome differences between
baseline and end-of-treatment were calculated for treat-
ment and control groups as well as differences between
treatment and control groups at end-of-treatment. Het-
erogeneity is discussed for each of these analyses.
Methods
Searching
We searched PUBMED, EMBASE and the Cochrane
Database until April 2012 using medical subject headings
related to epicondylitis when possible. The Search Key in-
cluded the following key words: tendinoses, tendinosis,
tendinitides, tendinitis, tendonitides, tendonitis, tendino-
pathy, epicondylalgia, epicondylitides, epicondylitis, tennis
elbow. Further we hand-searched references of systematic
reviews until April 2012 for additional studies. To identify
grey literature we searched clinicaltrials.gov for registered
RCTs on physical therapy for LE patients. Limits were set
to randomized controlled trials with adults (18 years and
older) and language restrictions were set to languages
spoken by the authors (i.e., English and German).
Selection
Studies were eligible if they investigated a physical ther-
apy intervention in comparison to a waiting-list control
group, treatment as usual control group or sham-control
group. If a study investigated a combination of therapy
modalities (e.g., extra corporeal shockwave therapy in
combination with manual therapy) the control group
would have to match one of the therapy modalities (e.g.,
only extra corporeal shock wave therapy or only manual
therapy). Orthoses, acupuncture, massage regimens, sur-
gery, pharmacological treatments and psychotherapy
were not included into the meta-analysis. Patients had to
be diagnosed with LE. All outcomes were considered for
inclusion as long as at least three studies used the same
outcome measurement. Studies had to report mean,
standard deviation and number of participants at base-
line and at the end of treatment.
Study design was limited to RCTs, and each group
under investigation had to consist of 10 or more patients.
Validity assessment
Four raters in groups of two independently rated the in-
cluded studies, using an adapted form of the SIGNChecklist for RCTs. The checklist consisted of eight
items evaluating the key question, randomization pro-
cedure, blinding, comparability of treatment and control
groups with respect to baseline measurements, study
procedure and additional therapies, validity of outcome
measurements, dropout rates and the use of intention-to-
treat analysis. The rating was conducted in three steps.
Differences in step one were resolved by exchanging cita-
tions between raters, followed by re-rating. Differences in
step 2 were resolved by discussion. Inter-rater reliability
was calculated by Cohen’s κ for each rating step and with
eight items per study.
Items were assessed either as “well”, “poor” or “not ad-
dressed”/“not reported”. If randomization (Item 1.2) was
rated as “not addressed” or “not reported”, the study was
excluded for not meeting RCT criteria. Studies in which
all aspects were rated as "well", were classified as Level
of Evidence (LoE) “++” for “good, very low risk of bias”.
If four or more aspects were rated as”poor” or “not ad-
dressed” the study was classified as LoE “-“for “poor,
high risk of bias”. Studies were also rated as LoE “poor,
high risk of bias” if the comparability of groups with re-
spect to study procedures was deemed compromised
(Item 1.6). Similar, if neither intention-to-treat analysis
was performed (Item 1.9) nor adequate blinding mea-
sures were employed (Item 1.4), the study was rated as
LoE “poor, high risk of bias”. All other studies were clas-
sified as LoE “+” “fair, low risk of bias”.
Data extraction
The following data were extracted from each study:
means and standard deviations of pain intensity, Disabil-
ities of the Arm, Shoulder and Hand (DASH) function
score, maximum handgrip strength in kg, pain during
maximum handgrip strength test, group size, type of
treatment, control group intervention, treatment dur-
ation, treatment frequency, assessment schedules and
time since diagnosis of LE. All pain scales were trans-
formed linearly to a 0–100 point scale. For scales from 0
to y: transformed MEAN =MEAN × (100 ÷ y). For scales
from 1 to y: transformed MEAN = (MEAN − 1) × (100 ÷
(y − 1)). Standard deviations were transformed as follows:
transformed SD = SD × (100 ÷ y) for scales from 0 to y;
transformed SD = SD × (100 ÷ (y − 1)) for scales from 1 to
y. All hand grip strength scales were transformed into
kg. If no minimum and maximum duration of illness
was reported, mean plus/minus two standard deviations
was used to estimate the interval which should include
about 95 % of participants.
Data were extracted by two independent investigators,
differences were solved by discussion. Since there was
only one LLLT study and one ECSWT study which re-
ported DASH scores, no further analysis was conducted
for physical function.
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Effect sizes were calculated by mean differences (MD).
Given standard errors were transformed into standard
deviations. No authors were contacted for missing data.
Statistical heterogeneity was assessed by I2 = [(Q – df)/Q]
× 100 %, where Q is the chi-squared statistic and df is its
degrees of freedom. I2 describes the percentage of the ef-
fect estimates variability which can be attributed to het-
erogeneity. Since effect sizes of studies testing against
waiting-list (WLC) or treatment as usual control groups
tend to be higher than those testing against sham-control
or active control groups, studies were split into three sub-
groups; 1) waiting-list or treatment as usual control
groups, 2) sham-control groups, and 3) studies which
compared a combination of two treatments to the single
application of one of those treatments. Publication bias
was assessed by Egger’s regression intercept using
Comprehensive-Meta-Analysis Software (CMA Software).
Statistical methods and outcomes
Results are reported as MD [95 % CI] (I2). Mean Differ-
ence (95 % Confidence Interval] (Heterogeneity); with
(s.) showing statistical significance and (n.s.) showing
non significance. Two types of MDs are being reported.
MDs between treatment and control groups are indi-
cated as “difference between treatment and control
groups”. MDs between baseline and end-of-treatment
are indicated as “difference from baseline”.
Results
Trial flow
Figure 1 shows a flow diagram of the selection processes.
One thousand one hundred thirty eight studies were
identified. One thousand seventy of those did not meet
inclusion criteria. The remaining 68 were retrieved as
full text articles and checked for inclusion and exclusion
criteria once again. Seventeen studies met all criteria
and were considered for quantitative synthesis. Twelve
of those reported comparable outcome measures. Since
only two studies [8, 9] investigated a combination of ther-
apies, each reporting different outcome measurements, nei-
ther study was included in the meta-analyses. Only one
study used a WLC design and therefore was excluded [10].
The remaining nine studies were included in the analysis;
three investigated LLLT, four ECSWT, one low frequency
electrical stimulation and one pulsed electromagnetic field
therapy (PEMF). There were not enough comparable
studies to evaluate any other treatment (Table 1).
Study characteristics
Quantitative data synthesis
Sixteen studies were included in the rating procedure
[8–23]. One study was rated as LoE “++” [11], 7 studies
were rated as LoE “+” [10, 15, 17–21] and 8 studies wererated as LoE “-“[8, 9, 12–14, 16, 22, 23]. Cohen’s κ was
calculated to assess inter-rater reliability for each rating
step κstep1 = 0.46; κstep2 = 0.83; κstep3 = 1.
In the end, five analyses could be conducted; the first
on the effect of physical therapy (ECSWT, LLLT, low fre-
quency electrical stimulation and PEMF) on pain; the
second on the effect of extracorporeal shockwave ther-
apy (ECSWT) on pain; the third on the effect of non-
ECSWT treatments (LLLT, low frequency electrical
stimulation and PEMF) on pain; the fourth on the effect
of LLLT on pain during maximum handgrip strength
tests, and the fifth on the effect of physical therapy treat-
ments (LLLT and ECSWT) on maximum handgrip
strength. The analysis on the effect of physical therapy
on physical functioning was not conducted due to the
heterogeneity of measurement instruments. Two studies
reported DASH (sports/music, work) scores, one DASH
function, one an adapted patient specific function scale,
and one the upper extremeties function scale. The
authors considered these scales too heterogeneous to
combine.
Review Manager Software (RevMan 5) by the Cochrane
Collaboration was used to conduct the five analyses.
All reported pain outcomes were transformed to a 0–
100 scale and all grip strength outcomes to kg.
Overall pain ECSWT, LLLT, low frequency electrical
stimulation and PEMF
Outcomes used were pain during the last 24 h, pain dur-
ing activity, pain during Thomsen Test, pain during day
and night, and pain at isometric testing.
Combined Pain relief in treatment groups (difference
from baseline) was −32.87 [95 % CI = −37.04, −28.70] (I2 =
18 %) (s.) (Fig. 2), with only one study [24] reporting pain
relief below 25. Combined Sham-control groups reported
−21.07 [95 % CI = −27.87, −14.27] (I2 = 65 %) (s.) (Fig. 3)
units of pain relief (difference from baseline). Comparing
pain intensity outcomes of treatment and control groups
at the end of treatment resulted in −7.50 [95 % CI =
−14.94, −0.07] (I2 = 78 %) (s.) (Additional file 1) units dif-
ference in pain reduction.
Overall pain ECSWT
If only ECSWT studies were analysed combined treat-
ment groups reported −34.79 [95 % CI = −39.98, −29.60]
(I2 = 24 %) (s.) (Fig. 4) units of pain relief (difference
from baseline). Combined Control groups in ECSWT
studies reported −24.48 [95 % CI = −32.65, −16.31] (I2 =
66 %) (s.) (Fig. 5) units of pain relief (difference from
baseline). Comparing pain intensity between ECSWT
and control groups at the end of studies resulted in a
statistically non significant pain reduction of −7.20 [95 %
CI = −17.44, 3.04] (I2 = 82 %) (n.s.) (Additional file 2).
Three of these four studies were of high methodological
Fig. 1 Flow diagram of the article selection process
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CI = −16.71, 6.46] (I2 = 82 %) (n.s.) (difference between
treatment and control groups).
Only two studies remained for a LLLT sub-group ana-
lysis. Thus, no effect size calculations were conducted.
Overall pain LLLT, low frequency electrical stimulation
and PEMF
Two LLLT studies, one low frequency electrical stimula-
tion study and one PEMF study reported sufficient data
to be analysed. Combined Non-ECSWT treatment groups
gained −29.35 [95 % CI = −35.84, −22.86] (I2 = 0 %) (s.)
(Fig. 6) units of pain relief (difference from baseline). The
respective combined control groups gained −16.38 [95 %CI = −27.08, −5.68] (I2 = 54 %) (s.) (Fig. 7) (difference from
baseline). Comparing treatment and control groups at the
end of trials resulted in a pain reduction of −8.12 [95 %
CI = −20.83, 4.60] (I2 = 71 %) (n.s.) (Additional file 3).
Pain during maximum handgrip strength tests
Three studies reported data on pain during maximum
handgrip strength tests, all investigating LLLT. Com-
bined treatment groups gained −19.16 [95 % CI =
−25.20, −13.11] (I2 = 0 %) (s.) (Additional file 4) units of
pain relief (difference from baseline). Control groups
gained −2.58 [95 % CI = −11.69, 6.52] (I2 = 33 %) (n.s.)
(Additional file 5) units of pain relief (difference from
baseline). Difference in pain intensity between treatment
Table 1 Studies considered for inclusion
Article Author Year Reported outcomes Treatment duration Times of measurements Symptom duration Treatment
[11] Basford et al. 2000 apain in last 24 h
maximal tenderness on palpation





[12] Bisset et al. 2009 reaction time 8S over 6 Ws 6, 52 Ws 6–89 Ms Physical therapy vs WLC
[13] Haake et al. 2002 side effects 1S/W over? Ws ? 1–99 Ms ECSWT vs placebo
[7] Ho et al. 2007 mechanical pain threshold 10S over 3 Ws 1, 2, 3 Ws, follow-up 3 Ws 3–15 Ms Microcurrent & exercise vs exercise
bpain-free handgrip strength
bmaximum handgrip strength
pain during max grip
[14] Lam et al. 2007 mechanical pain threshold 3S/W for 3 Ws Session 5, 9 & 3 Ws
after completion
1–9 Ms LLLT vs placebo
amaximum grip strength




[9] Martinez-Silvestrini et al. 2005 pain free grip strength Daily for 6 Ws 6 Ws 3+ Ms Stretching vs stretching & concentric vs
stretching & eccentric strengtheningbVAS pain
PRFEQ
bdash function
[15] Nourbakhsh et al. 2008 cmaximum grip strength 6S over 2–3 Ws Post treatment, follow-up 6–60 Ms Low frequency electrical stimulation
vs placeboapain intensity last 24 h
functional level (adapted patient
specific function scale)
limited activity due to pain
[10] Peterson et al. 2011 pain MVC 1S/D exercise
regimen over 3 Ms










1S/W over 3 Ws 1, 4, 8, 12 Ws; 6, 12 Ms
only reported at 12 Ws
















Table 1 Studies considered for inclusion (Continued)
[17] Rompe et al. 1996 night pain 1S/W over 3 Ws 3, 6, 24 Ws after
last application






cgrip strength (Mucha and Wannske)
[18] Rompe et al. 2001 pressure pain 1S/W over 3 Ws 12 Ws, 12 Ms 12–208 Ms ECSWT vs ECSWT +manual therapy
Thomsen test resisted finger extension
chair test
[19] Rompe et al. 2004 apain during Thomsen test 1S/W over 3 Ws 3, 12 Ms 12+ Ms ECSWT vs sham
Roles and Maudsley score
upper extremity function scale
bdynanometer test
[20] Speed et al. 2002 aPain (day and night)
night pain
50 % improvement from baseline
1S/M for 3 Ms 1; 2; 3 Ms 3–42 Ms ECSWT vs placebo
[21] Staples et al. 2008 aoverall pain index





pain free grip ratio













[22] Sterigioulas et al. 2007 pain at rest 2S/W over first 4 Ws
1S/W over second 4 Ws
8 Ws, 8 Ws after
end of treatment
5 Ws-12 Ys LLLT & exercise vs placebo and exercise
pain at palpation
apain on isometric testing
pain during middle finger test
apain during grip strength test
[47] Öken et al. 2008 Grip strength 5S/W over two weeks 2 Ws, 4 Ws after
end of treatment
1–24 Ms Ultrasound & hot pack vs LLLT & hot
pack vs brace control groupPain severety














Table 1 Studies considered for inclusion (Continued)
[23] Uzunca et al. 2007 resting pain 5S/W over 3 Ws 3 Ws, 3 Ms 1–11 Ms Pulsed electromagnetic field (PEMF)
vs sham PEMFaactivity pain
night pain
pain during resisted wrist
dorsiflexion pain during resisted forearm
supination
algometric pain threshold
Wweek, M month, S Session
aOutcome used in meta-analysis
bNot included due to control group design














Fig. 2 Overall pain relief in treatment groups
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CI = −22.65, 6.81] (I2 = 79 %) (n.s.) (Additional file 6).
Physical function
Only two studies remained for a physical function ana-
lysis. Thus, no effect size calculations were conducted.
Maximum handgrip strength
Three studies reported maximum grip strength, two in-
vestigating LLLT and one investigating ECSWT. Treat-
ment groups had mean maximum handgrip strength gain
of 6.47 kg [95 % CI = 3.68, 9.26] (I2 = 0 %) (s.) (Additional
file 7) (difference from baseline). Control groups had aFig. 3 Overall pain relief in sham-groupsmean maximum handgrip strength gain of 2.81 kg [95 %
CI = −1.25, 6.88] (I2 = 0 %) (n.s.) (Additional file 8) (differ-
ence from baseline). Comparison between treatment and
control groups at the end of studies showed a MD of
3.47 kg [95 % CI = 0.17, 6.76] (I2 = 0 %) (s.) (Additional
file 9) in favour of treatment groups. Since there was only
one ECSWT and two LLLT studies, no sub-group ana-
lyses were conducted.
Risk of bias across studies
Egger’s regression intercept showed no significant small
study effects for overall pain reduction t(6) = 1.83, p = 0.25;
overall pain reduction in ECSWT t(2) = 0.24; p = 0.83;
Fig. 4 Overall pain relief in ECSWT groups
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pain reduction during maximum handgrip strength tests
t(1) = 2.28; p = 0,26 and maximum handgrip strength t(1) =
0,47; p = 0,72.
Discussion
Summary of key findings
Two other meta-analyses have analyzed the effects of ei-
ther ECSWT [2] or LLLT [7] on LE. This meta-analysis
differs from its predecessors in two major aspects. One,
it tried to investigate a wide variety of physical treat-
ments, both in changes from baseline and differences
between treatment and control groups at the end of
treatment. Two, only completely published data was
used and no authors were contacted for further data.
All in all, treatment groups had between 29 and 35
units and control groups between 16 and 25 units of
pain relief. Differences between treatment and controlFig. 5 Overall pain relief in sham-ECSWT groupsgroups at the end of treatment were generally low, ran-
ging only from 7 to 9 units on a 0–100 scale. Of five
comparisons between treatment and placebo groups
only one, the combined analysis of ECSWT and non-
ECSWT studies, showed statistically significant results.
This finding should be interpreted with utmost reluc-
tance, since neither ECSWT studies alone, nor Non-
ECSWT studies alone showed statistically significant
differences between treatment and placebo groups. With
rather large pain relief scores in both, treatment and pla-
cebo groups, and only small differences between treat-
ment and placebo groups it can be concluded that a
large portion of therapy effects are attributable to con-
textual factors.
These findings resemble those of Buchbinder et al. [2]
who found that ECSWT is no more effective than placebo.
For pain at rest they report a MD (pain out of 100) of
−9.42 [95 % CI = −20.7, 1.86].
Fig. 6 Overall pain relief in Non-ECSWT treatment groups
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treatment of LE. In contrast to Bjordal et al. [7] this
meta-analysis identified only 2 LLLT studies which both,
met inclusion criteria and published sufficient data for
meta-analysis. This meta-analysis did not include six
studies which were included in Buchbinder et al. [2].
Five studies were excluded due to not reported standard
deviations [9, 13, 25–27], one was not included since the
underlying data is not published [28–35].
Since there were no authors contacted for this meta-
analysis a lower number of studies was to be expected.
Due to the small number of studies this meta-analysis
offers no interpretation concerning the effectiveness of
LLLT in the treatment for LE. Bjordal et al. [7] con-
cluded that LLLT was safe and effective and that it acted
in a dose dependent manner.
Pain relief during maximum handgrip strength tests
was generally lower than overall pain relief. TreatmentFig. 7 Overall pain relief in Non-ECSWT sham-groupsgroups had a mean pain relief of 19 units on a 0–100
scale and control groups had about 3 units. Still, differ-
ences in comparisons between those groups at the end
of treatment resulted in only 8 units of pain reduction
on a 0–100 scale, which might partly come from a shift
of weights in this analysis. Treatment groups’ maximum
handgrip strength improved by 6 kg while control groups
improved by 3 kg. The mean difference between treatment
and control groups at the end of treatment was 3 kg.
Both, Buchbinder et al. [2] and Bjordal et al. [7] expli-
citly state the need for further research. Buchbinder
et al. [2] especially criticize “a lack of uniformity in both
the timing of follow up and the outcomes that were
measured”. This meta-analysis found the same methodo-
logical heterogeneity. As can be seen in Table 1, treat-
ment duration, treatment intensity, symptom duration,
times of measurement and reported outcomes vary largely
between studies.
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Treatment groups showed more homogeneous outcomes
than we expected from the differing treatment modal-
ities (I2 = 18 %). The mean pain relief amounted to 32.9
units in treatment groups and to 21.1 units in control
groups. The difference between treatment and control
groups in mean pain relief amounted to 11.8 units on a
0–100 scale. Thus, control groups gained about 2/3 of
treatment groups’ overall pain relief. Differences between
ECSWT (34.8 units of pain relief ) and non-ECSWT
studies (30.4 units of pain relief ) only amounted to 4
units. This means that the difference between treatments
seems to be lower than the difference between treat-
ments and their respective control groups. If further
studies produced similar results this might indicate that
the decision which physical therapy treatment to use
(ECSWT, LLLTlow frequency electrical stimulation or
PEMF) might not be as important as maximizing non-
treatment specific effects.
During physical therapy patients do not only benefit
from the treatment itself, e.g., the pharmacological effect
of a drug or the physical effect of a laser therapy, but
also from non-treatment specific agents, the so called
sham-effects, placebo-effects or contextual effects [36].
Patients’ pain relief thus results from a combination of
treatment specific agents and non-treatment specific
agents. Important non-specific agents can be e.g., spon-
taneous remission, expectancy, motivation, conditioning
and other psychosocial agents [36].
With the combination of contextual and therapy-
specific factors about 95 % of patients in treatment
groups gained between 28 and 38 units of pain relief on
a 0–100 scale, compared to 14 to 28 units in control
groups and by contextual effects, only.
The difference between treatment and placebo groups
at the end of treatment was rather low. Still, only treat-
ment groups with their combination of specific and
unspecific agents managed to rather reliably reach clinic-
ally important pain relief of more than 22 units on a 0–
100 scale [37]. Patients in sham groups with their purely
unspecific agents only gained clinically relevant pain re-
lief in less than 50 % of cases.
Limitations
Altogether, for overall pain 473 patients were analyzed,
for pain during maximum handgrip strength test 136 pa-
tients and for maximum handgrip strength 193 patients.
These numbers are much lower than those reported of
patient collectives, studied e.g., in pharmaceutical trials
for WHO I (non-opioid analgesics) or WHO II (weak
opioids) analgesics which regularly evaluate over 100 pa-
tients per group per study [33, 38–46]. In the overall
pain analysis 318 of 473 patients were treated with
ECSWT, 97 with LLLT, 18 with low frequency electricalstimulation, and 40 with pulsed electromagnetic field
therapy. Thus, ECSWT results might be relatively stable
while non-ECSWT results might change, even with only
a few new studies.
Patients varied largely in their duration of symptoms,
making it impossible to differentiate between studies with
only acute or only chronic LE patients. Minimum symp-
tom duration varied between 4 weeks and 12 months,
maximum duration between 9 months and 17 years, with
several studies not reporting a cut-off point at all.
While some studies investigated treatment effects as
early as after the last treatment session, some studies let
several weeks or months pass before measuring post treat-
ment effects. Even though follow-up investigations help
understand the long-term effects of a therapy, a prolonged
period of time between the end of a treatment and the as-
sessment of its effectiveness may distort results. Especially
changes in patients’ activities or therapy regimen, as well
as social context may influence trial results.
Another distorting factor in this meta-analysis was the
rather large difference in treatment durations and ses-
sions per week. Studies went on over time periods of at
least three weeks to a maximum of three months. Dur-
ing this time treatments were applied a minimum of
once per month to a maximum of five sessions per week.
Thus, study effects were achieved with largely differing
efforts.
Still overall pain relief (I2 = 18 %), pain relief during
maximum handgrip strength tests (I2 = 0 %) and increase
in maximum handgrip strength (I2 = 0 %) in treatment
groups effects were mostly homogeneous. Only overall
pain relief in control groups (I2 = 65 %) showed great het-
erogeneity and pain relief during maximum handgrip
strength tests (I2 = 33 %) showed medium to low hetero-
geneity. Thus contributing to rather large heterogeneity in
the end of treatment comparisons of overall pain (I2 =
78 %) and pain during maximum handgrip strength tests
(I2 = 79 %).
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